Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin’s lymphoma

ObjectivesThis study was carried out to evaluate the role of quantitative parameters in staging PET in predicting prognosis in patients with high-grade non-Hodgkin’s lymphoma (NHL). MethodsA total of 51 histopathologically proven high-grade NHL patients treated with conventional chemotherapy regimens were included in the study. Total lesion glycolysis (TLG) and functional volumes (FVs) were defined as per the PET Response Criteria in Solid Tumors (PERCIST) criteria. All patients were followed up for a minimum period of 1 year or until an event, whichever occurred earlier. ResultsOf the four semiquantitative parameters studied, SUVmax and SUVmean did not show a statistically significant correlation with progression-free survival or overall survival, whereas TLG and FV showed a weak but statistically significant negative correlation. Using the receiver operating characteristic curve analysis, optimal cut-offs were derived for FV and TLG to predict progression and death. Using the cut-off values of 416 cm3 and 3340 g for FV and TLG, respectively, a statistically significant difference in progression-free survival and overall survival was obtained in the groups with FV and TLG above and below the threshold. On multivariate analysis of all the conventional prognostic factors and TLG more than 3340 and FV more than 416 cm3, only age greater than 60 years (P=0.013) and FV more than 416 cm3 (P=0.012) were found to be independently associated with disease progression. ConclusionOur results indicate that FV and TLG in staging PET/CT could be useful indices in predicting outcomes in patients with high-grade NHL treated with standard first-line chemotherapy regimens.

[1]  Ho-Jin Shin,et al.  Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma , 2012, Cancer science.

[2]  Philippe Bertrand,et al.  Interim positron emission tomography scan associated with international prognostic index and germinal center B cell-like signature as prognostic index in diffuse large B-cell lymphoma , 2012, Leukemia & lymphoma.

[3]  S. Mirzaei,et al.  Prognostic significance of the standardized uptake value of pre-therapeutic 18F-FDG PET in patients with malignant lymphoma , 2011, Medical oncology.

[4]  Seong-Jang Kim,et al.  Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement , 2011, Annals of Hematology.

[5]  Dimitris Visvikis,et al.  Baseline 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Y. Oki,et al.  High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma , 2011, International journal of hematology.

[7]  Florent Tixier,et al.  Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  M. Juweid FDG-PET/CT in lymphoma. , 2011, Methods in molecular biology.

[9]  A. Alavi,et al.  Current Evidence Base of FDG-PET/CT Imaging in the Clinical Management of Malignant Pleural Mesothelioma: Emerging Significance of Image Segmentation and Global Disease Assessment , 2011, Molecular Imaging and Biology.

[10]  S. Fujita,et al.  [Usefulness of metabolic volume and total lesion glycolysis for predicting therapeutic response in cancer therapy by 18F-FDG PET/CT]. , 2010, Kaku igaku. The Japanese journal of nuclear medicine.

[11]  H. Mak,et al.  Nasopharyngeal carcinoma: relationship between 18F-FDG PET-CT maximum standardized uptake value, metabolic tumour volume and total lesion glycolysis and TNM classification , 2010, Nuclear medicine communications.

[12]  Maximilien Vermandel,et al.  Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  R. Boellaard Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.

[14]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[15]  A. Alavi,et al.  Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET , 2008, Nuclear medicine communications.

[16]  F. Pons,et al.  Utilidad de la tomografía por emisión de positrones/ tomografía computarizada (PET/TC) en el estudio de extensión en pacientes con linfoma B difuso de células grandes , 2007 .

[17]  Emmanuel Itti,et al.  Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.

[18]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. López-Guillermo,et al.  [The value of positron emission tomography/computed tomography (PET/CT) in the staging of diffuse large B-cell lymphoma]. , 2007, Medicina clinica.

[20]  A. Nagler,et al.  Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[22]  E. Yoshikawa,et al.  Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  J. Itami,et al.  FDG-PET for predicting the prognosis of malignant lymphoma , 1994, Annals of nuclear medicine.

[24]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[25]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.